Compare Gilead Sciences, Inc. (GILD) vs Reddit Inc (RDDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Reddit Inc — how do they compare? Gilead Sciences, Inc. trades at $149.2 (market cap $182.40B), while Reddit Inc trades at $159.4 (market cap $30.10B). The key difference: Gilead Sciences, Inc. is far larger — about 6.1× Reddit Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Reddit Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Reddit Inc for 26 Days on average.
| GILD | RDDT | |
|---|---|---|
Market Cap | $182.40B | $30.10B |
Volume | 4,469,821 | 4,560,440 |
Sector | Health | Media |
52-Week High | $155.80 | $258.93 |
52-Week Low | $116.74 | $121.84 |
Typical Hold Time | 111 Days | 26 Days |
Enterprise Value | $205.46B | $27.34B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
RDDT trades at $160.63, up 5.14% over 24 hours, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability, with a net income margin of 31.35% and consecutive quarterly EPS beats. Recent news includes a partnership with Zefr for advertiser insights and a legal win against Anthropic, though concerns arise from the CEO's stock sale and the discontinuation of RSS feeds.
The outlook is positive, supported by robust earnings growth and a consensus price target of $202.52, implying significant upside. Key risks include competitive pressures in social media, potential regulatory scrutiny, and market volatility. Institutional ownership trends and analyst buy ratings (65.52%) reinforce a constructive view, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Reddit Inc
Reddit Inc. operates a vast network of online communities organized around various interests, known as 'subreddits'. Functioning as a hybrid of a social media platform and a discussion forum, the company generates revenue primarily through advertising and premium subscriptions. Reddit is a major hub for user-generated content, trending news, and viral discussions, and it is a key player in the digital advertising and social media landscape.
Read more on RDDT →
